Search Result
Results for "
weight loss
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N0132A
-
-
-
- HY-N0132
-
-
-
- HY-P1421
-
|
PERK
GHSR
Apoptosis
|
Metabolic Disease
|
Obestatin(human) is a 23-amino acid amidated peptide that regulates appetite and gastrointestinal motility via its interaction with GPR39. Obestatin(human) can be used for weight loss. Obestatin(human) cannot penetrate the cell membrane .
|
-
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
-
- HY-156830A
-
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
(4′R)-TGR5 Receptor Agonist 4 is the R enantiomer of TGR5 Receptor Agonist 4 (HY-156830). TGR5 Receptor Agonist 4 is an agonist of Bile Acid Receptor (TGR5), with EC50 for hTGR5 and mTGR5 of 2 nM and 3 nM, respectively. TGR5 Receptor Agonist 4 plays important roles in hypoglycemic and weight loss .
|
-
-
- HY-P10032
-
-
-
- HY-N0132B
-
Oxedrine hemitartrate
|
Adrenergic Receptor
Endogenous Metabolite
|
Neurological Disease
|
Synephrine (Oxedrine) hemitartrate, an alkaloid, is an α-adrenergic and β-adrenergic agonist derived from the Citrus aurantium. Synephrine hemitartrate is a sympathomimetic compound and can be used for weight loss .
|
-
-
- HY-N0132R
-
-
-
- HY-N0132AR
-
Oxedrine hydrochloride (Standard)
|
Reference Standards
Adrenergic Receptor
Endogenous Metabolite
|
Neurological Disease
Endocrinology
|
Synephrine (hydrochloride) (Standard) is the analytical standard of Synephrine (hydrochloride). This product is intended for research and analytical applications. Synephrine (Oxedrine) hydrochloride, an alkaloid, is an α-adrenergic and β-adrenergic agonist derived from the Citrus aurantium. Synephrine hydrochloride is a sympathomimetic compound and can be used for weight loss .
|
-
-
- HY-147927
-
|
Enteropeptidase
|
Metabolic Disease
|
Human enteropeptidase-IN-1 (compound 6b) is a highly potent, orally active and low systemic exposure enteropeptidase inhibitor. Human enteropeptidase-IN-1 boosts the increase in fecal protein output, and exhibits potent body weight loss in diet-induced obese (DIO) rat model. Human enteropeptidase-IN-1 can be used for anti-obesity research .
|
-
-
- HY-P3463
-
GLP-1 (human)
|
GCGR
|
Metabolic Disease
Inflammation/Immunology
|
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
|
-
-
- HY-N1437
-
-
-
- HY-N0930A
-
|
AMPK
Bacterial
|
Infection
Metabolic Disease
|
Galegine hemisulfate, a guanidine derivative, contributes to weight loss in mice. Galegine hemisulfate activates AMPK in 3T3-L1 adipocytes and L6 myotubes, as well as in the H4IIE rat hepatoma and HEK293 human kidney cell lines. Galegine hemisulfate has antibacterial activity, with minimum inhibitory concentration of 4 mg/L against Staphylococcus aureus strains .
|
-
-
- HY-N0930B
-
|
AMPK
Bacterial
|
Infection
Metabolic Disease
|
Galegine hydrochloride, a guanidine derivative, contributes to weight loss in mice. Guanidine hydrochloride is the compound derived from G. officinalis, which gave rise to the biguanides, metformin and phenformin. Galegine hydrochloride activates AMPK in 3T3-L1 adipocytes and L6 myotubes, as well as in the H4IIE rat hepatoma and HEK293 human kidney cell lines. Galegine hydrochloride has antibacterial activity, with minimum inhibitory concentration of 4 mg/L against Staphylococcus aureus strains .
|
-
-
- HY-147931
-
|
Enteropeptidase
|
Metabolic Disease
|
Human enteropeptidase-IN-2 (compound 1c) is a highly potent enteropeptidase inhibitor. Human enteropeptidase-IN-2 can be used for anti-obesity research .
|
-
-
- HY-U00070
-
-
-
- HY-B1834
-
|
Drug Metabolite
|
Inflammation/Immunology
Cancer
|
Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
|
-
-
- HY-P10985
-
|
Melanocortin Receptor
|
Metabolic Disease
|
CTX-1211 is a selective, orally effective melanocortin MC4R agonist (EC50=0.38 nM). CTX-1211 can enhance the feeding suppression and weight loss effects induced by liraglutide (HY-P0014), and promote anorexia and weight loss activity. CTX-1211 is mainly used in the study of obesity and other metabolic disorders .
|
-
-
- HY-159007
-
R,S-1,3-Butanediol acetoacetate diester
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
BD-AcAc2 is an orally active antiepileptic. BD-AcAc2 results in body weight loss or maintenance with moderate increases in circulating ketones .
|
-
-
- HY-B1834S1
-
-
-
- HY-N13223A
-
|
Others
|
Metabolic Disease
|
White Kidney Bean Extract (30:1) is the extract of White Kidney Bean. White Kidney Bean Extract (30:1) can be used in the study of obesity .
|
-
-
- HY-B1834R
-
|
Reference Standards
Drug Metabolite
|
Inflammation/Immunology
Cancer
|
Megestrol (Standard) is the analytical standard of Megestrol. This product is intended for research and analytical applications. Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
|
-
-
- HY-W747043
-
|
Isotope-Labeled Compounds
Drug Metabolite
|
Inflammation/Immunology
|
Megestrol-d3 is the deuterium labeled Megestrol (HY-B1834). Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
|
-
-
- HY-W269593
-
PFDA
|
Caspase
Interleukin Related
|
Metabolic Disease
|
Perfluorodecanoic acid (PFDA) is a perfluoroalkyl substance (PFAS). Perfluorodecanoic acid induces weight loss and increases liver weight and lipid content in mice. Perfluorodecanoic acid also reduces mRNA expression of the genes encoding IL-1β, IL-18, and cellular inhibitor of apoptosis 2 (cIAP2), as well as caspase-1, -3, and -7 in mouse liver .
|
-
-
- HY-156830
-
-
-
- HY-107734
-
|
Neuropeptide Y Receptor
|
Metabolic Disease
Endocrinology
|
L 152804 is an orally active and selective neuropeptide Y Y5 receptor (NPY5-R) antagonist, with a Ki of 26 nM for hY5. L 152804 causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure .
|
-
-
- HY-P10032A
-
-
-
- HY-147927A
-
|
Enteropeptidase
|
Metabolic Disease
|
(S)-Human enteropeptidase-IN-1 (Compound 6c) is an orally active enteropeptidase inhibitor with low systemic exposure (IC50 (initial): 26 nM; IC50 (app): 1.8 nM). (S)-Human enteropeptidase-IN-1 promotes increased fecal protein output and effectively reduces body weight in a diet-induced obese (DIO) rat model. (S)-Human enteropeptidase-IN-1 inhibits enteropeptidase via a reversible covalent mechanism and prolongs the enzyme inactivation time. (S)-Human enteropeptidase-IN-1 can be used in anti-obesity research .
|
-
-
- HY-N7347
-
Garcinia lactone
|
ATP Citrate Lyase
|
Metabolic Disease
|
(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .
|
-
-
- HY-114196
-
ZGN-1061
|
MetAP
|
Metabolic Disease
|
Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells .
|
-
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-W008581
-
3-O-Methyl estradiol; 17β-Estradiol 3-methyl ether; 3-Methoxyestradiol
|
Biochemical Assay Reagents
|
Endocrinology
|
Estradiol 3-methyl ether is a synthetic estrogen. Estradiol 3-methyl ether can disrupt microtubule networks in V79 cells with an EC50 of 9 μM, as well as inhibiting cell proliferation. Estradiol 3-methyl ether decreases the serum cholesterol levels and increases body weight loss, which indicates feminizing activity in HFD murine model .
|
-
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-153528
-
-
-
- HY-N7347R
-
Garcinia lactone (Standard)
|
Reference Standards
ATP Citrate Lyase
|
Metabolic Disease
|
(-)-Hydroxycitric acid lactone (Standard) is the analytical standard of (-)-Hydroxycitric acid lactone. This product is intended for research and analytical applications. (-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis .
|
-
-
- HY-12191
-
|
Histamine Receptor
|
Metabolic Disease
|
A-331440 is a potent and selective histamine H3 receptor antagonist that regulates neurotransmitter release by inhibiting presynaptic H3 receptors. In preclinical studies involving mice on a high-fat diet, A-331440 demonstrated dose-dependent effects on weight reduction and fat loss. At 5 mg/kg, it effectively decreased body weight comparable to dexfenfluramine, while at 15 mg/kg, it significantly reduced body fat and improved insulin tolerance, similar to mice on a low-fat diet. These findings suggest that A-331440 holds promise as an antiobesity agent by modulating histaminergic pathways involved in food intake and metabolic regulation .
|
-
-
- HY-172768
-
|
Bacterial
|
Infection
|
SCUT1-2 is a bifunctional antibacterial agent with good oral bioavailability in mice (F=56.8%). SCUT1-2 can kill the vegetative cells of C. difficile with a MIC of 0.06-0.50 μg/mL, and inhibit spore germination in vitro. SCUT1-2 could alleviate the symptoms of weight loss and diarrhea in mice caused by C. difficile infection (CDI) and prevent recurrent CDI .
|
-
-
- HY-B0723
-
FC-1271a
|
Estrogen Receptor/ERR
Caspase
|
Neurological Disease
Endocrinology
Cancer
|
Ospemifene (FC-1271a) is an orally active and non-estrogenic selective estrogen receptor modulator (SERM) with Ki values of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene inhibits caspase-3 activity. Ospemifene inhibits neuronal degeneration, prevents bone loss, and increases vaginal weight and vaginal epithelial height. Ospemifene has anticancer activity against breast cancer .
|
-
-
- HY-W127851
-
Cypridina luciferin analog
|
Biochemical Assay Reagents
|
Others
Cancer
|
CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.
|
-
-
- HY-126360
-
|
TNF Receptor
Interleukin Related
|
Inflammation/Immunology
|
Oxazolone is a haptenizing agent that induces acute or chronic inflammation of the large intestine and is used to construct models of colitis. Oxazolone can cause Th1/Th2-dependent colitis with weight loss and diarrhea. Oxazolone-induced inflammation can be mitigated by neutralizing anti-IL-4 or anti-TNF-α antibodies or decoy IL-13R2-α-FC proteins .
|
-
-
- HY-175039
-
|
FAK
Apoptosis
Reactive Oxygen Species (ROS)
Caspase
|
Cancer
|
FAK-IN-28 is an orally active FAK inhibitor (IC50 = 0.4 nM). FAK-IN-28 exhibits dual antiproliferative and anti-metastatic properties. FAK-IN-28 triggers caspase-3-dependent apoptosis via ROS elevation. FAK-IN-28 inhibits tumor growth without causing weight loss or hepatotoxicity. FAK-IN-28 is useful in the study of FAK-driven malignancies, such as colon cancer, cervical cancer, triple-negative breast cancer, and melanoma .
|
-
-
- HY-170237
-
|
Salt-inducible Kinase (SIK)
|
Cancer
|
SIK2/3-IN-1 (Compound 7S) is a selectively inhibitory agent of SIK2/3 with oral activity. SIK2/3-IN-1 can significantly inhibit tumor growth (without any body weight loss) in the MV4-11 AML mice CDX model. SIK2/3-IN-1 can be used in the research of MEF2C-dependent acute myeloid leukemia .
|
-
-
- HY-103151A
-
|
5-HT Receptor
|
Others
|
CP94253 is a selective, orally active agonist for serotonin receptor 1B (5-HT1B), through competitive binding with iodocyanopindolol (ICP) to the 5-HT1 receptor. CP94253 binds to the 5-HT1B, 5-HT1A, 5-HT1D, 5-HT1C and 5-HT2 receptors, with Kis of 2, 89, 49, 860 and 1600 nM. CP94253 causes satiety, anorexia, weight loss and hyperlocomotion in rats model .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-W127851
-
Cypridina luciferin analog
|
Biochemical Assay Reagents
|
CLA, or conjugated linoleic acid, is a polyunsaturated fatty acid that occurs naturally in a variety of animal products, such as meat and dairy. It has several potential benefits for human health, including the ability to reduce body fat mass, improve insulin sensitivity, and reduce inflammation. CLA has been extensively studied for its effects on weight loss and muscle growth, as well as its potential role in preventing chronic diseases such as heart disease and cancer. Additionally, it can be taken as a dietary supplement in capsule form.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1421
-
|
PERK
GHSR
Apoptosis
|
Metabolic Disease
|
Obestatin(human) is a 23-amino acid amidated peptide that regulates appetite and gastrointestinal motility via its interaction with GPR39. Obestatin(human) can be used for weight loss. Obestatin(human) cannot penetrate the cell membrane .
|
-
- HY-P3462A
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P3462
-
|
CGRP Receptor
|
Metabolic Disease
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P10032
-
-
- HY-P3463
-
GLP-1 (human)
|
GCGR
|
Metabolic Disease
Inflammation/Immunology
|
Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
|
-
- HY-P10032A
-
-
- HY-P2231
-
MEDI0382
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P2231A
-
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P10985
-
|
Melanocortin Receptor
|
Metabolic Disease
|
CTX-1211 is a selective, orally effective melanocortin MC4R agonist (EC50=0.38 nM). CTX-1211 can enhance the feeding suppression and weight loss effects induced by liraglutide (HY-P0014), and promote anorexia and weight loss activity. CTX-1211 is mainly used in the study of obesity and other metabolic disorders .
|
-
- HY-P3568
-
Grybi-AKH
|
Peptides
|
Metabolic Disease
|
Adipokinetic hormone Gryllus bimaculatus (Grybi-AKH) is an adipokinetic hormone that regulates energy homeostasis in insects by mobilizing lipid and carbohydrate from the fat body. Adipokinetic hormone Gryllus bimaculatus stimulates the locomotor activity of the two-spotted cricket. Adipokinetic hormone Gryllus bimaculatus can also be used in studies to regulate body weight, induce weight loss and alleviate glycogen storage disorders in humans .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1834S1
-
|
Megestrol-d5 is the deuterium labeled Megestrol. Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
|
-
-
- HY-W747043
-
|
Megestrol-d3 is the deuterium labeled Megestrol (HY-B1834). Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: